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1. Introduction 
Both prescription drugs and illicit substances have been associated with the formation of 
aortic aneurysms, ruptures of aortic aneurysms, and acute aortic dissections. Most of the 
clinical information exists as single case reports and case series, but causal relationships 
have for many drug groups been substantiated on the basis of the known mechanisms of 
action of the drugs as well as from experimental studies in animals. 
For abdominal aneurysms, the most important etiologic factors include systemic 
hypertension, hyperlipidemia and atherosclerosis. In theory, all drugs having a negative 
impact of one or more of these factors might increase the risk of aortic aneurysms. On the 
other hand, drugs positively influencing these factors, such as antihypertensives and 
cholesterol-lowering drugs, could, at least in theory, have a potentially protective effect on 
the formation and development of the aneurysms. For aortic dissections, systemic 
hypertension is a central risk factor, and many drugs known to increase systemic blood 
pressure abruptly are associated with aortic dissections. In addition, abrupt discontinuation 
of antihypertensive drugs known to cause rebound hypertension, such as the beta blockers, 
may precipitate aortic dissections.  
The objective of this chapter is to present a comprehensive review of pharmaceutical 
products and illicit substances associated with the formation and ruptures of aortic 
aneurysms. Moreover, drugs implicated in acute aortic dissections are also included. Data 
from case reports and case series are tabulated for completeness. When relevant, these data 
are also synthesised in order to provide aggregate information, attempting to identify 
potential drug-specific risk factors. Results from experimental studies are included to 
provide an understanding of the underlying mechanisms, and treatment options are 
discussed when they deviate from conventional therapy. 
2. Methods 
This chapter is a literature review based upon the author’s research experience with adverse 
drug reactions, supplied by a search in the database PubMed, primarily by using the 
medical subject heading (MeSH) term “aortic aneurysm” with the subheading “chemically 
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induced”. Such a search strategy revealed 185 articles, which were scrutinised. The reference 
lists in the articles were further checked to identify other studies and reports of interest.  
3. Drugs associated with aortic aneurysms 
3.1 Glucocorticoids 
Ruptures of aortic aneurysms are not unknown in autoimmune disorders affecting connective 
tissue in various organ systems including blood vessels, such as systemic lupus erythematosus 
(SLE) and rheumatoid arthritis (Smith & Hirst, 1979; Sato et al., 2003; Ohara et al., 2000a, 
2000b). In such cases glucocorticoids may have a protective effect by inhibiting the activity of 
the underlying disorder. However, it has also been suspected that glucocorticoid use could 
have a precipitating role by increasing blood pressure, blood cholesterol and blood glucose 
levels, thereby causing atherosclerosis, as well as by increasing the fragility of blood vessels 
due to its negative effects on collagen formation and connective tissue strength (Smith & Hirst, 
1979; Sato et al., 2003; Ohara et al., 2000a, 2000b).  
In the literature, a total of 14 cases have been reported after long-term glucocorticoid use in 
patients with autoimmune disorders affecting connective tissue (Table 1). In these cases, it is 
by no means obvious whether the rupture is caused by the underlying disease, the 
treatment with glucocorticoids, or a combination thereof. There are no reports of ruptured 
aortic aneurysms during long-term treatment with glucocorticoids for disorders and 
conditions not affecting connective tissue, such as glomerulonephritis, or after organ 
transplantations. However, there are in addition two cases of ruptures after short-term 
treatment with glucocorticiods for disorders not causing weakness of connective tissue 
(Mellingsæter et al., 2009), but on the other hand, these patients also had additional risk 
factors, such as advanced age (Table 1).  
The gender distribution of the 16 cases identified in the literature (Table 1), with 50 % males 
and 50 % females, seems to reflect the gender distribution of the underlying disorders. As 
expected, the mean age is also relatively low, 56 years. 
Experimental evidence of an association between the use of glucocorticoids and aortic 
aneurysm rupture is found in an animal study (Reilly et al., 1990). In that study, genetically 
susceptible mice had a higher risk of developing aortic aneurysms, as well as having a 
rupture of the aneurysms, when treated with hydrocortisone. When the genetically 
susceptible mice were given hydrocortisone for 14 days, the mean aortic diameter increased 
to 1.86 mm, as compared to a stable value of 0.93 mm in a control group of genetically 
normal mice. In another experiment presented in the same publication (Reilly et al., 1990), 
nine of the 10 genetically susceptible mice died during the 21-day trial with hydrocortisone 
(6 with proven aortic rupture, 3 with presumed rupture), and also the 10th mouse in this 
group had an aneurysm after 21 days. The death risk was dose-dependent, with an average 
survival of 14 days among mice receiving the two higher hydrocortisone doses, as compared 
to 18-21 days among mice receiving the two lower doses. 
In conclusion, long-term treatment with glucocorticoids has been associated with aortic 
aneurysm ruptures in numerous case reports, but it is not clear whether the ruptures have 
been caused by the underlying disease, the drug treatment, or combinations thereof. 
However, based on the known pharmacological effects of glucocorticoids as well as an 
experimental study, a causal association is not unlikely, although published evidence 
implies that this adverse drug reaction is very infrequent.  
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Reference 
Age, 
gender
Drug, dose, duration 
of treatment
Location of the 
aneurysm
Underlying disease/ 
predisposing factors 
Smith  
et al., 1979 
55, 
male
Prednisolone 10 mg/d 
for 11 years
Descending 
thoracal
Rheumatoid arthritis 
Smith  
et al., 1979 
68, 
female
Prednisolone 15 mg/d 
for “many years”
Descending 
thoracal
Rheumatoid arthritis 
Stehbens  
et al., 1993 
56, 
male
Glucocorticoids (NS) 
for 16 years
Infrarenal SLE 
Seyama  
et al., 1989 
54, 
male
Glucocorticoids (NS) 
for 1.5 years
Upper 
abdominal
SLE 
Kurata  
et al., 1985 
43, 
female
Glucocorticoids (NS) 
for 10 years
Descending 
thoracal
SLE 
Higashina 
et al., 1990 
33, 
female
Glucocorticoids (NS) 
for 18 years
Descending 
thoracal
SLE 
Sato  
et al., 19951 
45, 
female
Glucocorticoids (NS) 
for 27 years
Infrarenal 
Progressive systemic 
sclerosis 
Sato  
et al., 19951,2 
52, 
female
Glucocorticoids (NS), 
mean 3.5 mg/d for 
16 years
Descending 
thoracal/ 
infrarenal
SLE 
Sato  
et al., 19951 
73, 
female
Glucocorticoids (NS) 
for 15 years
Infrarenal 
Rheumatoid arthritis; 
advanced age 
Sato  
et al., 19951,2 
75, 
female
Glucocorticoids (NS), 
mean 3.2 mg/d for 
32 years
Infrarenal SLE; advanced age 
Sato  
et al., 19951,2 
43, 
female
Glucocorticoids (NS), 
mean 2.8 mg/d for 
22 years
Infrarenal SLE 
Ohara  
et al., 2000a2 
34, 
male 
Glucocorticoids (NS), 
mean 4.1 mg/d for 
21 years
Infrarenal SLE 
Ohara  
et al., 2000b 
73, 
male 
Glucocorticoids (NS), 
mean 2.5 mg/d for 
1 year
Infrarenal SLE; advanced age 
Hussain  
et al., 1998 
40, 
male
Glucocorticoids (NS) 
for 15 years
Ascending 
thoracal
SLE 
Melling-
sæter  
et al., 2009 
77, 
male 
Prednisolone 40 mg/d 
for 4 days 
Descending 
thoracal 
Pyoderma 
gangrenosum/ 
advanced age; 
previous aorta 
aneurysm3 
Melling-
sæter  
et al., 2009 
82, 
male 
Prednisolone 60 mg/d 
for 9 days and  
30 mg/d for 5 days
Abdominal 
Bullous pemphigoid/ 
advanced age 
Abbreviations: NS = not specified; SLE = systemic lupus erythematosus 
1 The same case is also included in the case series by Ohara et al., 2000a 
2 The same case is also included in the case series by Ohara et al., 2000b 
3 Previously treated with a stent graft in the abdominal part of a thoraco-abdominal aortic aneurysm 
Table 1. Published cases of glucocorticoid-associated aortic aneurysm ruptures 
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3.2 Antihypertensive drugs  
Based upon evidence from animal studies, activation of the renin-angoitensin-aldosteron 
system seems to be a central factor in the development of aortic aneurysms (Daugherty et 
al., 2006; Lu et al., 2008; Miyake & Morishita, 2009). In a population-based case-control study 
of more than 15,000 patients with abdominal aortic aneurysms (3,379 with ruptures and 
11,974 without ruptures), treatment with angiotensin converting enzyme (ACE) inhibitors 
before admission was associated with a reduced risk of ruptures (adjusted Odds Ratio [OR] 
0.83; 95 % confidence interval [CI] 0.73-0.95). In contrast, protective effects were not found 
for beta-blockers, calcium antagonists, alpha-blockers or thiazide diuretics. Thus, the 
beneficial effect of ACE inhibitors on the risk of ruptures seems to be independent of the 
antihypertensive effect (Hackam et al., 2006). Those who during the last months had 
discontinued treatment with ACE inhibitors, had on the other hand a marginally higher risk 
of ruptures (adjusted OR 1.39; 95 % CI 1.09-1.77). In contrast to the above findings, 
angiotensin receptor blockers (ARBs), which also inhibit the renin-angoitensin-aldosteron 
system, were not found to have any protective effect (adjusted OR 1.24; 95 % CI 0.71-2.18). 
However, this apparent discrepancy may be caused by a type II error, as only 132 patients in 
the entire material used ARBs (Hackam et al., 2006).  
Inconsistent with the ACE inhibitor findings cited above, a recent prospective cohort study 
of 1,701 patients with small abdominal aortic aneurysms found that the growth rate of the 
aneurysms in fact was higher (3.33 mm/year) in the 169 patients treated with ACE 
inhibitors than in the remaining patients (2.77 mm/year; p=0.009) (Sweeting et al., 2010). No 
such associations were found for other groups of antihypertensive drugs. 
It should also be noted that in a case-control study, use of calcium antagonists was 
significantly associated with the occurrence of aortic aneurysms (adjusted OR 2.6; 95 % CI 
1.5-4.2), whereas no other antihypertensive drug groups showed an increased risk 
(Wilmink et al., 2002). In the same study, patients exposed to calcium antagonists also had 
an increased aortic wall stiffness. Nevertheless, there was no association between calcium 
antagonists (or with any of the other drug groups) and the growth rate of the aneurysms 
after they had been detected. The association between calcium antagonist use and the 
occurrence of aortic aneurysms is consistent with the finding in an animal study in which 
the calcium antagonist amlodipine accelerated the degradation of elastin (Boyle et al., 
1998). 
All observational studies, including those cited above, are inevitably subject to bias and 
confounding. Thus, there is an urgent need for prospective, randomised, controlled trials to 
elucidate the role of both ACE inhibitors, ARBs, calcium antagonists and other groups of 
antihypertensives as to whether they have a protective, neutral or provoking effect on the 
formation and growth of aortic aneurysms and the risk of ruptures. 
4. Drugs assosiated with aortic dissections 
4.1 Phosphodiesterase-5 inhibitors 
The phospodiesterase-5 (PDE-5) inhibitors sildenafil, tadalafil and vardenafil are widely 
used to cause penile erection in patients with impotence. An association between sildenafil 
and acute aortic dissection has been suspected in three case reports (Table 2). Hitherto, no 
cases have been reported for tadalafil and vardenafil.  
As all the three patients reported in the literature had predisposing factors for aortic 
dissection (Table 2), the causal role of sildenafil has been questioned. One patient used 
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isosorbide mononitrate concomitantly. Combinations of PDE-5 inhibitors with nitrates and 
other nitric oxide donors, including nitroglycerin and isosorbide mono- or dinitrate, are 
contraindicated due to the risk of excessive increases in systemic blood pressure. Also sexual 
arousal is associated with increased blood pressure, which could have been a contributing 
factor. However, at least in one of the patients, the aortic dissection appeared before sexual 
intercourse took place. 
 
Reference 
Age, 
gender
Drug, dose 
Temporal 
relationship
Predisposing factors 
Stanford 
type 1 
Famularo  
et al., 2001 
42, male
Sildenafil 
50 mg 
1 hour after 
intake 
Cocaine sniffing 2 hours 
earlier, heavy smoker 
B 
Nachtnebel 
et al., 2006 
61, male
Sildenafil 
50 mg 
30 min after 
intake 
Hypertension, 
concomitant use of 
isosorbide mononitrate 
A 
Tiryakioglu 
et al., 2009 
28, male
Sildenafil 
50 mg 
2 hours after 
intake 
Bicuspid aortic valve with 
ascending aortic 
aneurysm 
A 
1 Stanford type A: All dissections involving the ascending aorta, regardless of the site of origin.  
Stanford type B: All dissections not involving the ascending aorta 
Table 2. Published cases of phosphodiesterase-5-associated aortic dissections 
In addition to the risk of increasing systemic blood pressure, at least when combined with 
nitrates and other nitric oxide donors, sildenafil has vasorelaxant and antiproliferative 
effects on pulmonary vascular smooth muscle cells. Due to these effects it is also used in 
patients with pulmonary hypertension. Although not substantiated experimentally, it has 
been speculated that a similar antiproliferative effect in the aorta as in the pulmonary artery 
might cause a thinner media due to smooth muscle cell loss, rendering the aortic wall more 
vulnerable to dissections (Nactnebel et al., 2006). 
In conclusion, sildenafil and possibly also other PDE-5 inhibitors have the potential to 
increase systemic blood pressure in certain situations, thus being able to provoke aortic 
dissections in vulnerable individuals.  
4.2 Vascular endothelial growth factor inhibitors 
Vascular endothelial growth factor (VEGF) inhibitors are a drug group inhibiting vascular 
proliferation and promoting apoptosis of cells participating in the formation of new blood 
vessels. As VEGF expression is increased in a variety of tumors, VEGF inhibitors are 
primarily used in the treatment of malignant diseases. An association between acute aortic 
dissection and treatment with the VEGF inhibitors sorafenib, sunitinib and bevacizumab has 
been suspected on the basis of three case reports, summarised in Table 3. 
Hypertension is one of the major adverse drug reactions of VEGF inhibitors. For sorafenib 
and sunitinib, overall incidences of 23.4 and 22.5 % have been reported in meta-analyses 
(Wu et al., 2008). For bevacizumab, the incidence of hypertension in studies included in a 
meta-analysis ranged from 2.7 % to 32 % during low-dose treatment and between 17.6 % 
and 36 % during high-dose treatment (Zhu et al., 2007). In most cases, the increased blood 
pressure can be treated with antihypertensive drugs, but a minority of patients will not 
respond to antihypertensive therapy and the VEGF inhibitor has to be discontinued.  
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Reference 
Age, 
gender
Drug 
Temporal 
relationship
Predisposing factors 
Stanford 
type1 
Aragon-
Ching  
et al., 2008 
70, 
male 
Bevaci-
zumab 
After 28 
cycles of be-
vacizumab 
for 21 days 
Hypertension for 25  
years, increased 
considerably after 10 
months of bevacizumab 
treatment 
B 
Edeline  
et al., 2010 
58, 
male 
Sunitinib 
After 4 
cycles of 
sunitinib for 
28 days 
None; no increase in 
systemic blood pressure 
observed during sunitinib 
treatment 
B 
Serrano  
et al., 2010 
77, 
female
Sorafenib
After 3 
cycles of 
sorafenib for 
21 days 
Advanced age B 
1 Stanford type A: All dissections involving the ascending aorta, regardless of the site of origin.  
Stanford type B: All dissections not involving the ascending aorta 
Table 3. Published cases of vascular endothelial growth factor inhibitor-associated aortic 
dissections 
The pathogenetic mechanism behind VEGF inhibitor-induced hypertension remains 
uncertain. It has been suggested that as VEGF inhibitors also block the effects of other 
growth factors including platelet-derived growth factor (PDGF), and as PDGF plays a role in 
blood vessel tonus regulation and microvascularisation, this could be a possible mechanism 
(Edeline et al., 2010). However, closely related protein kinase inhibitors such as imatinib, 
dasatinib and nilotinib, which inhibits PDGF without inhibiting VEGF, are not particularly 
linked to hypertension. On this basis, a direct effect via VEGF inhibition seems more likely. 
The involvement of VEGF in the formation of normal blood vessels during embryonic 
development and in the carcinogenesis is well studied, but its possible function in normal 
blood vessels in adults is unclear. Suggested mechanisms include impaired angiogenesis at 
the microcirculation level, endothelial dysfunction associated with decreased levels of the 
vasodilator nitric oxide which is normally stimulated by VEGF, and alterations in the renin-
angiotensin-aldosteron system (Sica, 2006).  
Based upon the high incidence of hypertension during treatment with VEGF inhibitors, 
patients treated with these drugs should be closely followed with blood pressure 
measurements. If hypertension develops, it should be treated adequately. Obviously, as 
hypertension is a well-known risk factor for aortic dissection, also VEGF inhibitor-induced 
hypertension will increase the risk of aortic dissection. 
4.3 Antihypertensive drugs 
Antihypertensive drugs are known to protect a vulnerable aorta from dissections, and 
discontinuation of such drugs could therefore be expected to increase the risk of acute 
dissections. In particular antihypertensive drugs for which rebound hypertension occur 
after abrupt discontinuation, such as beta-blockers and clonidine, would be expected to 
increase the risk of aortic dissections.  
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One single case of acute aortic dissection has been reported within a short time interval 
after abrupt discontinuation of antihypertensive drug treatment (Eber et al., 1993). A 60-
year-old man treated with beta-blockers for hypertension for 20 years developed a 
Stanford type A dissection two days after stopping metoprolol. It is not explicitly stated in 
the report whether the drug was tapered down before discontinuation or stopped 
abruptly, but is seems likely that treatment ceased directly from a dose of 50-100 mg/day. 
In such cases rebound effects including increased blood pressure, tachycardia and cardiac 
arrhythmias, and in some cases even cardiac infarction and sudden cardiac death, may 
occur (Houston & Hodge, 1988; Psaty et al., 1990). Therefore, current recommendations 
state that beta-blockers (and clonidine) should be tapered over at least 1-2 weeks before 
discontinuation. 
4.4 Other drugs 
Anticoagulants and fibrinolytic drugs have in two case reports been associated with aortic 
dissections and ruptures of thoracic aortic aneurysms. The first case was an 80-year-old 
woman who developed a Stanford type B aortic dissection during treatment with warfarin 
(Blunt & Impallomeni, 2004). Notably, her International Normalised Ratio (INR) was 4.8, 
indicating a considerably increased bleeding risk. The authors speculate that the underlying 
mechanism was a bleeding into an atheromatous plaque in the thoracic aorta. The second 
case was a 67-year-old man who was treated with the tissue plasminogen activator (t-PA) 
nateplase due to an acute ischemic stroke and who developed a rupture of a thoracic aortic 
aneurysm (Hayashi et al., 2004). The authors suggest that the t-PA infusion caused the 
rupture, based upon some evidence that plasminogen activators are able to degrade 
abdominal aortic aneurysms (Reilly, 1996).  
A single case report of aortic dissection exists in a patient receiving chemotherapy for cancer 
(Golden et al., 1997). The patient was a 42-year-old man treated with cyclophosphamide, 
vincristine, procarbazine, prednisolone, bleomycin and vinblastine for Hodgkin’s disease. 
As many of these agents are known to cause endothelial cell damage, the authors postulate 
that a toxic effect to endothelial cells in the aortic wall was the underlying mechanism. 
However, the patient also had other risk factors, including hypercholesterolemia and 
tobacco smoking. Thus, a causal relationship between the cytotoxic drugs and the aortic 
dissection remains obscure, and, if the suggested underlying mechanism is correct, it is 
remarkable that no more reports are found in the literature.  
Numerous other drugs than those presented earlier in this review have the ability of causing 
hypertension. Consequently, these drugs might, at least in theory, increase the risk of aortic 
dissections. Common for these drugs is that there are no published case reports of aortic 
dissections related to their use. Whether the reason for the lack of such reports is that the 
relationship has not been recognised, or it is that the excess risk is so low that it can be 
considered negligible, is unknown. Drugs known to increase systemic blood pressure 
include sympathomimetic substances like adrenaline, noradrenaline, dopamine, 
metaraminol and phenylephrine, which might cause excessive elevations in blood pressure 
when the dose or, when given as an infusion, the rate of infusion, is not carefully controlled. 
Other drugs known to cause hypertension as an adverse drug reaction include non-steroidal 
antiinflammatory drugs (NSAIDs), ciclosporin and venlafaxine, just to mention a few. 
Moreover, monoamine oxidase inhibitors induce excessive hypertension when indirectly 
acting sympathomimetic drugs or tyramine-rich food or beverages are ingested 
concomitantly (Davies & Davies, 1998).   
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4.5 Illicit drugs 
4.5.1 Cocaine  
The association between cocaine abuse and aortic dissection is well documented. In some 
case series of patients with aortic dissection the proportion caused by cocaine abuse is 
relatively high. For example, in a material from a US urban hospital, 14 of the 38 cases of 
aortic dissection registered between 1981 and 2000 (37 %) were related to cocaine use (Hsue 
et al., 2002). In another US study, (Singh et al., 2007), 13 of 46 cases (28 %) diagnosed 
between 1996 and 2005 were associated with cocaine. Finally, in a chart review for the 
period 1990-2006, 16 of 163 patients (9.8 %) had used cocaine the last 24 hours before 
symptom onset (Daniel et al., 2007). In contrast, only 0.5 % of the cases in the International 
Registry for Aortic Dissection were found to be related to cocaine (Eagle et al., 2002). The 
proportion found to be caused by cocaine abuse will clearly depend on the frequency of 
cocaine use in the population from which the subjects originate. Moreover, cases associated 
with cocaine use will not be revealed if the patients are not explicitly asked about cocaine 
use or preferably tested for the presence of the cocaine metabolite benzoylecgonine in urine.  
In addition to these four more systematic studies (Hsue et al., 2002; Eagle et al., 2002; Daniel 
et al., 2007; Singh et al., 2007), numerous single cases, summarised in Table 4, are reported in 
the literature.  
Based on the 16 cases detailed by Daniel et al. (2007) and the 19 cases presented in Table 4, 
subjects with cocaine-related aortic dissections seem to be younger than average. All were 
younger than 60 years of age, three of four were younger than 50, and the mean age was 44 
years. In total, 77 % were males. Almost all were long-term users, many had a history of 
uncontrolled hypertension, and the dissections occurred shortly after intake of cocaine. In 
some cases, symptoms appeared during or within the first few minutes after ingestion, but 
there could also be a lag-time of up to 24 hours – with one possible exception; an apparent lag-
time of 3 days is reported in one case (Divakaran et al., 2007). In both the studies by Hsue et al. 
(2002) and by Daniel et al. (2007), the mean lag-time was 12 hours. However, based upon the 
19 single cases (Table 4), the median lag-time could be estimated to about 1.5-2 hours, only. 
It has been suggested that Stanford type B dissections are more common among cocaine 
users than in the average population (Singh 2007). However, according to Daniel et al. 
(2007), it was not apparent that type B dissections were more common. Of the 16 cases 
presented by Daniel et al. (2007) plus the 19 case reports (Table 4), 54 % were of type A 
whereas 46 % were of type B. As a comparison, 62 % were of type A and 38 % of type B in a 
general material consisting of 464 patients with acute aortic dissection (Ince et al., 2007).   
It has been claimed that both the recurrence risk and the mortality of aortic dissections could 
be higher among cocaine users than among subjects with dissections unrelated to cocaine use 
(Hsue et al., 2002). The most likely reason for a possibly increased recurrence risk is continued 
cocaine use after discharge; there is no data available indicating that the recurrence risk would 
be increased in patients able to seize cocaine abuse after the first episode of dissection. 
The effects of cocaine on the cardiovascular system are caused by its sympathomimetic 
properties. Cocaine predominantly exerts its pharmacological effects by blocking the 
reuptake of noradrenaline and dopamine from the synaptic cleft into presynaptic neurons. 
Increased levels of noradrenaline in the synaptic cleft activate postsynaptic alpha-adrenergic 
and beta-adrenergic receptors. An enhanced release of noradrenaline into the synaptic cleft 
by cocaine may also take place, causing further receptor activation. Activation of alpha-1 
receptors in blood vessels causes elevation of the systemic blood pressure through 
vasoconstriction. Activation of beta-1 receptors in the heart promotes ventricular 
contractility and increases heart rate, thereby contributing to the effects on blood pressure. 
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Reference 
Age, 
gender
Route of 
administration
Interval between 
intake and 
symptom onset 
Predisposing 
factors 
Stanford 
type1 
Barth  
et al., 1986 
45, 
male
Inhalation Hours Hypertension A 
Edwards & 
Rubin, 1987 
41, 
male
Insufflation 30 min Hypertension B 
Grannis  
et al., 1988 
46, 
male
Insufflation 1.5 hours Hypertension B 
Gadaleta  
et al., 1989 
45, 
male
Insufflation Unknown Hypertension A 
Fischer & 
Holroyd, 
1992 
58, 
male 
Subcutaneously 5 min Hypertension B 
Om  
et al., 1992 
47, 
male
Intravenously 
Unknown; died 
before surgery
Hypertension A 
Cohle & Lie, 
1992 
35, 
male 
Inhalation 
Unknown; found 
dead 
NR A 
Simons  
et al., 1992 
26, 
female
Insufflation Unknown NR A 
Adkins  
et al., 1993 
43, 
male 
Inhalation During smoking NR A 
McDermott 
et al., 1993 
37, 
male
Inhalation 12-18 hours Hypertension B 
Sherzoy  
et al., 1994 
50, 
female
Inhalation 2 hours Hypertension B 
Rashid  
et al., 1996 
42, 
male 
Inhalation 40 min Hypertension A 
Perron & 
Gibbs, 1997 
33, 
male 
Inhalation Unclear None A 
Hohm, 
1995 
28, 
male 
NR Unclear None A 
Baumgartner 
& Omari, 
1997 
40, 
female
NR NR NR A 
Madu  
et al., 1999 
34, 
female
Inhalation 2 hours Hypertension B 
Divakaran  
et al., 2007 
45, 
male
NR 3 days? NR A 
Johnson  
et al., 2008 
48, 
male
Inhalation “Short” Hypertension A 
Szeberin  
et al., 2009 
35, 
male
NR NR NR B 
Abbreviations: NR = not reported 
1 Stanford type A: All dissections involving the ascending aorta, regardless of the site of origin.  
Stanford type B: All dissections not involving the ascending aorta 
Table 4. Published cases of cocaine-associated aortic dissections 
www.intechopen.com
  
Etiology, Pathogenesis and Pathophysiology of Aortic Aneurysms and Aneurysm Rupture 
 
168 
The sudden and considerable increase in blood pressure shortly after intake of cocaine 
obviously will increase shear stress in the aorta, sometimes causing a disruption of the 
intima and a dissection. More infrequently, the stress may produce an intramural hematoma 
that subsequently may rupture into the lumen (Scherzoy et al., 1994; Singh et al., 2010). In 
addition, long-term cocaine use may impair the elastic properties of the aorta, thereby 
reducing the ability of the aortic wall to withstand fluctuations in blood pressure and shear 
stress (Bigi et al., 2008).  
As for aortic dissection of other causes, the immediate treatment of cocaine-induced 
dissections is to lower the blood pressure. In general, beta-blockers are most often used for 
this purpose. However, for cocaine-related dissections, beta-blockers should be avoided 
because they do not antagonise the alpha-adrenergic effects and may thus exacerbate, or at 
least not counteract, cocaine-related vasoconstriction of the coronary and visceral arteries 
(Lange et al., 1990; Hollander, 2008; Singh et al., 2010). The combined alpha- and beta-
blocker labetalol would therefore, at least in theory, be a better choice. However, labetalol 
does not reverse the vasoconstriction of the coronary arteries fully, most likely because its 
alpha-antagonistic properties are too weak (Boehrer et al., 1993; Hollander, 2008). 
Nevertheless, some authors still recommend the use of labetalol. Alternative treatments 
include nitroglycerin, which reverse the cocaine-induced vasoconstriction of the coronary 
arteries to a sufficiently high degree, and verapamil (Lange & Hills, 2001). Also 
nitroprusside and hydralazine have been suggested, although these drugs, which do not 
exert beta-blocking properties, in fact may increase the shear stress of the aorta further due 
to reflex tachycardia with a subsequent increase in cardiac output (Hollander, 2008; Singh et 
al., 2010). 
4.5.2 Methamphetamine, amphetamine and 3,4-methylenedioxymethamphetamine 
(MDMA; ecstasy) 
There are numerous case reports of acute aortic dissection related to methamphetamine,  
and a few case reports exist for the closely related agents amphetamine and 3,4-
methylenedioxymethamphetamine (MDMA; ecstasy) (Table 5). For simplicity, these three 
substances are described as “amphetamines” in this chapter. Among the 13 cases published 
in detail in the literature (Table 5), all were males. Their mean age was 38 years, and none 
were older than 52, thus resembling the situation for cocaine users and reflecting the 
characteristics of the population using these illicit drugs. In nine of the 11 cases where the 
type of dissection was reported (81 %), the dissections were Stanford type A. 
In a systematic review of 35 deceased patients with aortic dissection screened for drug use 
in California during the years 1987-1996, seven (20 %) tested positive for methamphetamine 
(Swalwell & Davis, 1999). Whereas the mean age in the total group was 52 years, the mean 
age among those who tested positive for methamphetamine was 41 years. In six of the seven 
cases (86 %), the dissection was of type A. Thus, the characteristics of this group are similar 
to those of the 13 cases published in detail (Table 5). 
In a population-based study of 3,116 aortic dissections in subjects aged 18 to 49 years 
(Westover & Nakonezny, 2010), abuse and dependence of amphetamines were significantly 
associated with aortic dissections (OR 3.33, 95 % CI 2.37-4.69). Interestingly, the OR for 
abuse and dependence of amphetamines was lower than for Marfan syndrome (OR = 374), 
cardiovascular syphilis (OR = 106), bicuspid aorta valve (OR = 45), Takayashu disease  
(OR = 31), Turner syndrome (OR = 22), Ehlers-Danlos syndrome (OR = 13), giant cell 
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arthritis (OR = 6.5), hypertension (OR = 7.7), coarctation of the aorta (OR = 4.6) and motor 
vehicle accidents (OR = 3.6), but higher than for cocaine abuse/dependence (OR = 1.6), 
tobacco use (OR = 1.4), and age (OR = 1.1). The higher risk for the amphetamines than for 
cocaine is somewhat surprising on the basis of the number of published cases in the 
literature. One possible explanation for the increased risk might be that the amphetamines 
most likely have a prolonged effect on the blood pressure increments as compared to 
cocaine, due to a slower elimination from the body.   
 
Reference 
Age, 
gender
Drug 
Temporal 
relationship
Predisposing 
factors
Stanford 
type1 
Davis & 
Swalwell, 1994 
52, 
male 
Methamphetamine Not known2
Hypertension, 
also positive 
for cocaine
A 
Davis & 
Swalwell,  1994
42, 
male
Methamphetamine Not known2 Hypertension NR 
Davis & 
Swalwell,  1994
28, 
male
Methamphetamine Not known2 None NR 
Kim et al., 
1999 
37, 
male
Methamphetamine Not known None A 
Wako et al., 
2007 
39, 
male
Methamphetamine Not known3 None A 
Wako et al., 
2007 
37, 
male
Methamphetamine Not known3 Hypertension B 
Wako et al., 
2007 
38, 
male
Methamphetamine Not known3 Hypertension B 
Wako et al., 
2007 
35, 
male
Methamphetamine Not known3 None A 
Wako et al., 
2007 
44, 
male
Methamphetamine Not known3 Hypertension A 
Wako et al., 
2007 
44, 
male
Methamphetamine Not known3 Hypertension A 
Obioha, 
2009 
42, 
male 
Methamphetamine 2 days None A 
Dihmis et al., 
1997 
27, 
male
Amphetamine Not known2 NR A 
Duflou & Mark, 
2000 
29, 
male
MDMA (ecstasy) 
Possibly 12 
hours2
None A 
Abbreviations: MDMA = 3,4-methylenedioxymethamphetamine; NR = not reported 
1 Stanford type A: All dissections involving the ascending aorta, regardless of the site of origin.  
Stanford type B: All dissections not involving the ascending aorta 
2 Patient deceased, intake detected by post-mortem toxicological screening 
3 Intake identified by drugs-of-abuse screening in urine 
Table 5. Published cases of aortic dissections associated with methamphetamine, ampheta-
mine and 3,4-methylenedioxymethamphetamine (ecstasy) 
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Like cocaine, the amphetamines exert their stimulating effects by increasing available 
noradrenaline and dopamine in the brain synapses. However, in contrast to cocaine, the 
effect is predominantly mediated by enhancing the release of neurotransmitters from 
presynaptic neurons rather than by inhibiting the reuptake. Nevertheless, the final 
common pathway for cocaine and the amphetamines is activation of adrenergic alpha and 
beta receptors, thereby causing elevation of systemic blood pressure through 
vasoconstriction and increased ventricular contractility and heart rate, respectively (see 
also section 4.5.1). 
It has not been stated in the literature whether specific antihypertensive drugs should be 
preferred for dissections caused by amphetamines. However, based on the mechanism of 
action, it seems reasonable to consider the same treatments for amphetamine- as for cocaine-
related dissections. Thus, beta-blockers should be avoided because they would be expected 
to exacerbate, or at least not counteract, the tendency to cause vasoconstriction of the 
coronary and visceral arteries (see also section 4.5.1). The beta-blocker esmolol has 
nevertheless been suggested as the drug of choice in a recent case report (Obioha et al., 
2009), but the authors of this report have, somewhat surprisingly, not discussed the 
potential risks with beta-blocker treatment in these patients.  
5. Conclusions 
The only drug group for which relatively clear-cut evidence of involvement in the formation 
and rupture of aortic aneurysms exists, is the glucocorticoids. In addition, there is 
inconsistent evidence from epidemiological studies regarding whether the various 
antihypertensive drug classes protect against or in fact may precipitate growth and ruptures 
of aortic aneurysms. Prospective controlled clinical trials in this area are urgently needed to 
elucidate this issue. 
Drug groups implicated in aortic dissection include those known to increase systemic blood 
pressure, such as phosphodiesterase-5 inhibitors like sildenafil, and vascular endothelial 
growth factor inhibitors like sorafenib, sunitinib and bevacizumab. Moreover, abrupt 
discontinuation of antihypertensive drugs known to cause rebound hypertension after 
cessation of therapy, such as beta-blockers, may also cause aortic dissection. In addition, 
single case reports exist for a few other drugs. Finally, illicit drugs such as cocaine, 
amphetamine, methamphetamine and ecstasy are associated with acute aortic dissections, 
with relative risk increases in the order of magnitude of about 2-3. Thus, the increased risk 
of aortic dissection for these substances is presumably considerably higher than for legal 
medicines. 
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